GlassScriptPhysician profile
Harold Joseph Einsig
NPI 1023119526
$1,440.86
in general payments reported to CMS, 2019-2025
13 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $174 · 2021: $94.99 · 2022: $184 · 2023: $283 · 2024: $101 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $860.08 | 2019-2025 | Wavewriter Alpha Prime 16, Infinion 16 |
| Abbott Laboratories | $199.26 | 2019-2025 | Proclaim |
| Averitas Pharma INC. | $65.05 | 2023-2025 | Qutenza |
| Glaxosmithkline, LLC. | $64.63 | 2022-2023 | Benlysta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.44 | 2023 | Relistor |
| Merz Pharmaceuticals, LLC | $50.77 | 2022-2023 | Xeomin |
| Electronic Waveform Lab, INC. | $36.70 | 2019-2020 | |
| Si-Bone, INC. | $24.26 | 2019 | |
| Biotronik Nro, INC. | $18.32 | 2025 | Prospera |
| Abbvie INC. | $16.74 | 2023 | |
| Bioventus LLC | $16.59 | 2025 | Durolane |
| Collegium Pharmaceutical, INC. | $13.80 | 2023 | Belbuca |
| Allergan, INC. | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Einsig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.